Karyopharm (KPTI) Q4 2025 earnings review
Survival Hinges on March Data as Cash Runway Tightens
Karyopharm has entered a binary window. While Q4 XPOVIO sales grew 10% YoY to $32.1M and operating losses narrowed significantly due to cost cuts, the financial clock is ticking. Cash stands at just $64.1M, providing a runway only into Q2 2026—coinciding exactly with the expected release of pivotal Phase 3 SENTRY data in Myelofibrosis this March. Management explicitly flagged 'substantial doubt' regarding the ability to continue as a going concern. The investment thesis has shifted entirely from commercial execution to a binary clinical event: positive SENTRY data likely unlocks financing and survival; failure leaves the company with a massive debt pile and insufficient liquidity.
🐂 Bull Case
Top-line data from the Phase 3 SENTRY trial (Myelofibrosis) is due in March 2026. Management projects a peak revenue opportunity of ~$1B. Blinded safety data suggests lower anemia rates than standard of care, potentially positioning selinexor + ruxolitinib as the new frontline standard.
Management has successfully slashed cash burn. Q4 Loss from Operations improved 43% YoY ($17.8M vs $31.3M in 24Q4). This discipline maximizes the meager cash pile ahead of the data readout.
🐻 Bear Case
Cash runway extends only into Q2 2026. With $64.1M on hand and high debt levels, the company has zero margin for error. A negative or equivocal SENTRY read could close capital markets to them.
Interest expense rose to $12.6M in Q4 (up from $11.2M YoY). The company recorded a massive $62.4M loss on debt extinguishment in FY25. The capital structure is stressed, and servicing debt consumes cash needed for commercialization.
⚖️ Verdict: 🔴
Speculative. The core XPOVIO business is stable but insufficient to fund the company. KPTI is effectively a binary option on the March 2026 SENTRY data. High risk, high reward, with significant solvency risk if the trial fails.
Key Themes
Going Concern Warning
The earnings release explicitly notes 'substantial doubt exists regarding Karyopharm's ability to continue as a going concern.' Cash dropped from $109M at year-end 2024 to $64M currently. Without a capital raise triggered by positive data, the company faces an existential crisis by mid-year.
SENTRY Trial Readout (Myelofibrosis)
This is the primary catalyst. Data is due in March 2026. Management highlighted blinded safety data from the first 61 patients showing potential improvements in anemia (extrapolated 26% Grade 3/4 vs 37% historical SOC). Success here opens a $1B market; failure likely caps the company's upside indefinitely.
Endometrial Cancer Opportunity
The Phase 3 XPORT-EC-042 trial reads out mid-2026. Long-term follow-up from the prior SIENDO trial showed a median PFS of 39.5 months in the p53 wild-type/pMMR subgroup (vs ~13 months for placebo). This represents a significant 'second shot on goal' if SENTRY data is mixed.
Operational Efficiency
Accelerating cost cuts. R&D expense dropped 17% YoY to $27.7M, and SG&A dropped 16% to $22.8M. This is not just 'trimming fat' but a necessity for survival. The company successfully reduced Loss from Operations by 43% in Q4, demonstrating rigorous adherence to austerity.
XPOVIO Plateau
Stable. U.S. Net Product Revenue is growing, but slowly (up 9.6% in Q4 YoY). FY26 guidance ($115-$130M) implies flat-to-13% growth over FY25 ($115M). While it provides a base, XPOVIO in Multiple Myeloma is not growing fast enough to solve the liquidity crisis on its own.
Other KPIs
Decelerating significantly (worsening), primarily due to a $62.4M non-cash loss on debt extinguishment and $10M in other expenses (fair value remeasurements). Excluding these one-offs, operating loss actually improved, but the headline number highlights the cost of their complex capital structure.
Stable. Up 9.6% YoY and up roughly 7% sequentially vs Q3 ($30.5M). Demand is consistent, particularly in the community setting (60% of volume). However, competitive pressures in Multiple Myeloma remain high.
Accelerating. Up from $11.2M in 24Q4. The rising cost of debt service is consuming a significant portion of the $32M in quarterly product revenue, hindering the path to breakeven.
Guidance
Stable/Decelerating. FY25 Actual was $146M. The midpoint ($140M) implies a YoY decline, likely due to lower expected license/milestone revenue compared to FY25 ($31M in FY25). This puts more pressure on product sales.
Stable/Accelerating. Midpoint ($122.5M) implies ~6.5% growth over FY25 ($114.9M). This confirms the 'mature product' status of XPOVIO in its current indications—it is a cash cow, not a growth engine.
Stable. FY25 Actual was ~$230M. Guidance implies flat spending despite the need to prepare for a potential Myelofibrosis launch, indicating continued strict cost control.
Critical. The runway barely covers the release of SENTRY data (March 2026). This confirms the company effectively has zero buffer for delays or negative data.
Key Questions
Contingency for SENTRY Failure
With cash running out in Q2 2026 and 'substantial doubt' on going concern status, what is the specific Plan B if SENTRY data is equivocal or negative? Is a sale of the XPOVIO asset on the table?
Launch Prep Funding
You are guiding for flat OpEx in FY26. If SENTRY is positive, how will you fund the commercial ramp-up and inventory build for Myelofibrosis without blowing through the remaining cash before a capital raise can be executed?
Debt Covenants
Given the tight liquidity, are there any specific covenants in the senior secured term loan that could be triggered by the current cash trajectory prior to the Q2 2026 runway end?